Innovative Pharmaceutical Biotech (HKG:0399) entered a memorandum of understanding to invest in US-based Niraxx in exchange for a majority stake, a Tuesday Hong Kong bourse filing said.
Niraxx developed SyncWell, an artificial intelligence-powered virtual health platform, and DeepSynaps, a neurotechnology service platform.
Niraxx is also in the business of integrating photobiomodulation technology into activewear and developing a computer chip that integrates advanced technologies.
The oral insulin products seller said the potential investment is part of the group's business diversification efforts.
The parties have yet to enter a formal agreement, as stated in the disclosure.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。